First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis.

BMJ Open · 2023 · PMC10729208 · PMID 38101853

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Specifically, D+CT led to a significant increase in progression-free survival (PFS) and showed a positive trend towards improved OS. 11 However, the high costs of these novel medications have raised concerns about affordability and the economic impact of such treatments.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.